From COPD to cancer: indacaterol’s unexpected role in combating NSCLC
Indacaterol, a potential inhibitor of GLUT1, has significant antitumor effects on NSCLC. Moreover, the combination of indacaterol with immune checkpoint inhibitors may further enhanced the inhibitory effects of indacaterol on NSCLC cells. Our study provides scientific evidence supporting the clinical application of indacaterol as a novel therapeutic strategy for NSCLC treatment.
Authors
- Min Jiang (ORCID: https://orcid.org/0000-0002-3413-6307)
- Honglei Chen (ORCID: https://orcid.org/0000-0002-5860-4734)
- Jiaqi Huang (ORCID: https://orcid.org/0000-0002-6514-3075)
- Chenghao Liu (ORCID: https://orcid.org/0000-0001-7976-1264)
- Pei Cai (ORCID: https://orcid.org/0000-0001-5022-6145)
Institutions
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Taiwan Centers for Disease Control (TW)
- Karamay Central Hospital of Xinjiang (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.3389/fphar.2025.1579126
- Citations
- 1
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Chinese Academy of Sciences
- Government of Jiangsu Province
- Wuhan University
- Zhongnan Hospital of Wuhan University
- Institute of Hydrobiology